

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinopharm Tech Holdings Limited

國藥科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8156)

VOLUNTARY ANNOUNCEMENT THE CUMULATIVE QUANTITY OF THE COMMERCIAL CONTRACTS EXCEEDED 25 MILLION UNITS PER YEAR ON AVERAGE OF ANTI-COUNTERFEITING PRODUCTS ANTI-COUNTERFEITING BUSINESS PROGRESS

This announcement is made by Sinopharm Tech Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep the shareholders and potential investors of the Company informed of the latest business development of the Group.

As at the date of this announcement, the Group is pleased to announce that, benefiting from the results of the anti-counterfeiting business team in actively developing new customers, the cumulative quantity of the commercial contracts that has been entered into for Guoke innovative anti-counterfeiting products (“**Guoke Innovative Anti-counterfeiting Products**”) has exceeded 25 million units per year on average, reaching a new height. This is an indication that the market development of Guoke Innovative Anti-counterfeiting Products business has been effective in terms of expanding into new industries in tandem with deeper penetration into industries that we had previously established. The Group believes that the recent increase in business volume as well as the higher market recognition that comes from the beginning of the delivery of Guoke Innovative Anti-counterfeiting Products, will bring sustainable growth to the anti-counterfeiting business of the Group based on the complete virtuous business loop of Guoke Innovative Anti-counterfeiting Products.

Guoke Innovative Anti-counterfeiting Products with patented technologies have four main features, namely, “anti-counterfeiting”, “credibility”, “marketing” and “social responsibility” while using the complete chain of anti-counterfeiting system together with anti-counterfeiting packaging and online anti-counterfeiting information verification platform as the core. Guoke Innovative Anti-counterfeiting Products can perform with various functions and properties depending on different application scenarios, redefining the traditional anti-counterfeiting technology and attracting consumers to actively participate in the authentication of products. Through the “Trio Code” (三碼合一) entrance, consumers could easily enter the online anti-counterfeiting information verification platform, forming a closed loop of functions, such as authentication of products and interactive marketing, thus creating a unique way of marketing.

The Group's strategy to implement across industry and across region commercialization of anti-counterfeiting products is beginning to bear fruit. In view of the nature of replicable business model of Guoke Innovative Anti-counterfeiting Products, the Group is confident in continuing to apply and expand the coverage of Guoke Innovative Anti-counterfeiting Products into various consumer product markets. With rich experience in working with customers from the various industries, the Group will summarize the characteristics of the needs of each industry and the pattern of the cooperation models, to lay a solid foundation for achieving across industry and across region goals in order to strengthen our position in the market.

Guoke Innovative Anti-counterfeiting Products is a Corporate Social Responsibility ("CSR")-enabling product. The Group, through Guoke Innovative Anti-counterfeiting Products, is providing its customers with the tools to achieve a greater level of CSR. The very nature of Guoke Innovative Anti-counterfeiting Products embeds the elements of consumer protection as well as contributing to the social welfare and sports development while consumer protection and welfare funding contribution are two of the most important elements in any CSR matrix. By leveraging the capabilities of the Guoke Innovative Anti-counterfeiting Products regarding brand protection and brand endorsement, it is expected to support the sustainable development of the brand, achieve prosperity of the industries and its high-quality development and promote rural vitalization. By using Guoke Innovative Anti-counterfeiting Products, the corporate users will be able to achieve CSR in an effective way. The wide and extensive reach of Guoke Innovative Anti-counterfeiting Products in consumer products will take CSR to a new level of achievement. The Group will also be able to achieve and enhance the Group's participation in CSR through supplying Guoke Innovative Anti-counterfeiting Products.

By order of the Board
Sinopharm Tech Holdings Limited
國藥科技股份有限公司
CHAN Ting
Chairperson

Hong Kong, 20 December 2021

As at the date of this announcement, the Board comprises Mr. CHAN Ting, Mr. LIAO Zhe and Mr. CHEUK Ka Chun Kevin as executive Directors, Madam CHEUNG Kwai Lan and Dr. CHENG Yanjie as non-executive Directors and Mr. LAU Fai Lawrence, Dr. LIU Ta-pei and Mr. CHAU Wai Wah Fred as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Listed Company Information" page of the GEM website at www.hkgem.com for a minimum period of 7 days from the date of its publication and on the website of the Company at www.sinopharmtech.com.hk.